Genmab A/S
GMAB
$21.78
$0.110.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.57% | 33.98% | 18.63% | 27.96% | 47.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.57% | 33.98% | 18.63% | 27.96% | 47.67% |
| Cost of Revenue | 55.56% | 164.77% | 248.69% | 793.49% | -- |
| Gross Profit | 16.84% | 30.43% | 14.71% | 24.08% | 41.06% |
| SG&A Expenses | 0.80% | 32.38% | 1.49% | 6.75% | 28.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.21% | 37.37% | 14.04% | 31.11% | 39.84% |
| Operating Income | 62.07% | 28.17% | 26.89% | 22.16% | 93.07% |
| Income Before Tax | -2.01% | 254.10% | -35.04% | 24.00% | 549.68% |
| Income Tax Expenses | -14.04% | -179.13% | -19.24% | 97.78% | 606.43% |
| Earnings from Continuing Operations | 1.56% | 441.45% | -39.29% | 4.15% | 534.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.56% | 441.45% | -39.29% | 4.15% | 534.55% |
| EBIT | 62.07% | 28.17% | 26.89% | 22.16% | 93.07% |
| EBITDA | 58.73% | 30.39% | 27.22% | 22.31% | 85.67% |
| EPS Basic | 3.57% | 456.87% | -37.55% | 5.46% | -7.44% |
| Normalized Basic EPS | 13.47% | 332.02% | -37.24% | 34.21% | 18.71% |
| EPS Diluted | 3.93% | 457.77% | -37.42% | 5.67% | -7.48% |
| Normalized Diluted EPS | 13.85% | 332.53% | -37.10% | 34.47% | 18.66% |
| Average Basic Shares Outstanding | -1.93% | -2.77% | -2.77% | -1.24% | 585.54% |
| Average Diluted Shares Outstanding | -2.28% | -2.88% | -2.99% | -1.43% | 585.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |